The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
Abstract
BACKGROUND: Pathomorphologic brain changes occurring as early as first-episode schizophrenia have been extensively described. Longitudinal studies have demonstrated that these changes may be progressive and associated with clinical outcome. This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia. OBJECTIVE: To test a priori hypotheses that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treated patients and that gray matter and lateral ventricle volume changes are associated with changes in psychopathology and neurocognition. DESIGN: Longitudinal, randomized, controlled, multisite, double-blind study. Patients treated and followed up for up to 104 weeks. Neurocognitive and magnetic resonance imaging (MRI) assessments performed at weeks 0 (baseline), 12, 24, 52, and 104. Mixed-models analyses with time-dependent covariates evaluated treatment effects on MRI end points and explored relationships between MRI, psychopathologic, and neurocognitive outcomes. SETTING: Fourteen academic medical centers (United States, 11; Canada, 1; Netherlands, 1; England, 1). PARTICIPANTS: Patients with first-episode psychosis (DSM-IV) and healthy volunteers. INTERVENTIONS: Random allocation to a conventional antipsychotic, haloperidol (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d). MAIN OUTCOME MEASURES: Brain volume changes assessed by MRI. RESULTS: Of 263 randomized patients, 161 had baseline and at least 1 postbaseline MRI evaluation. Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not. A matched sample of healthy volunteers (n = 58) examined contemporaneously showed no change in gray matter volume. CONCLUSIONS: Patients with first-episode psychosis exhibited a significant between-treatment difference in MRI volume changes. Haloperidol was associated with significant reductions in gray matter volume, whereas olanzapine was not. Post hoc analyses suggested that treatment effects on brain volume and psychopathology of schizophrenia may be associated. The differential treatment effects on brain morphology could be due to haloperidol-associated toxicity or greater therapeutic effects of olanzapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Dynamics of Gray Matter Loss in Alzheimer's Disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., Herman, D., Hong, M. S., Dittmer, S. S., Doddrell, D. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00994.2003 · Cited by 1,132
Automated model-based tissue classification of MR images of the brain
Van Leemput, K., Maes, F., Vandermeulen, D., & Suetens, P. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.811270 · Cited by 1,024
The reduced neuropil hypothesis: a circuit based model of schizophrenia
Selemon, L. D., & Goldman-Rakic, P. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00281-9 · Cited by 909
Lawrie, S. M., & Abukmeil, S. S. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.172.2.110 · Cited by 843
Lewis, D. A., & Lieberman, J. A. (2000) · Neuron · doi:10.1016/s0896-6273(00)00111-2 · Cited by 811
Self-citation
Cited by
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
A Structural MRI Study of Human Brain Development from Birth to 2 Years
Knickmeyer, R. C., Gouttard, S., Kang, C., Evans, D., Wilber, K., Smith, J. K., Hamer, R. M., Lin, W., Gerig, G., & Gilmore, J. H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3479-08.2008 · Cited by 1,151
Ho, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.199 · Cited by 971
van Erp, T. G. M., Walton, E., Hibar, D. P., Schmaal, L., Jiang, W., Glahn, D. C., Pearlson, G. D., Yao, N., Fukunaga, M., Hashimoto, R., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.023 · Cited by 934
Toga, A. W., Thompson, P. M., & Sowell, E. R. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.007 · Cited by 872
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860
Ellison-Wright, I., Glahn, D. C., Laird, A. R., Thelen, S. M., & Bullmore, E. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07101562 · Cited by 620
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Velakoulis, D., Wood, S. J., Wong, M. T. H., McGorry, P. D., Yung, A., Phillips, L., Smith, D., Brewer, W., Proffitt, T., Desmond, P., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.139 · Cited by 597
Pantelis, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi034 · Cited by 573
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Self-citationEarly intervention for psychosis
Marshall, M., & Rathbone, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004718.pub3 · Cited by 531
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512
Cytokines and schizophrenia: microglia hypothesis of schizophrenia
Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508
Onitsuka, T., Shenton, M. E., Salisbury, D. F., Dickey, C. C., Kasai, K., Toner, S. K., Frumin, M., Kikinis, R., Jolesz, F. A., & McCarley, R. W. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1603 · Cited by 508
Hedman, A. M., van Haren, N. E. M., Schnack, H. G., Kahn, R. S., & Hulshoff Pol, H. E. (2012) · Human Brain Mapping · doi:10.1002/hbm.21334 · Cited by 484
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Cortical Thickness and Subcortical Volumes in Schizophrenia and Bipolar Disorder
Rimol, L. M., Hartberg, C. B., Nesvåg, R., Fennema-Notestine, C., Hagler, D. J., Pung, C. J., Jennings, R. G., Haukvik, U. K., Lange, E., Nakstad, P. H., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.036 · Cited by 454
Vita, A., De Peri, L., Deste, G., & Sacchetti, E. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.116 · Cited by 453
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Salisbury, D. F., Kuroki, N., Kasai, K., Shenton, M. E., & McCarley, R. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.521 · Cited by 379
Changes in Cortical Thickness During the Course of Illness in Schizophrenia
van Haren, N. E. M. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.88 · Cited by 378
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Gogtay, N., & Thompson, P. M. (2010) · Brain and Cognition · doi:10.1016/j.bandc.2009.08.009 · Cited by 347
Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
KESHAVAN, M., TANDON, R., BOUTROS, N., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.020 · Cited by 347
Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings
Navari, S., & Dazzan, P. (2009) · Psychological Medicine · doi:10.1017/s0033291709005315 · Cited by 336
The Myth of Schizophrenia as a Progressive Brain Disease
Zipursky, R. B., Reilly, T. J., & Murray, R. M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs135 · Cited by 334
Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis
Fusar-Poli, P., Borgwardt, S., Crescini, A., Deste, G., Kempton, M. J., Lawrie, S., Mc Guire, P., & Sacchetti, E. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.005 · Cited by 332
Progressive Gray Matter Reduction of the Superior Temporal Gyrus During Transition to Psychosis
Takahashi, T., Wood, S. J., Yung, A. R., Soulsby, B., McGorry, P. D., Suzuki, M., Kawasaki, Y., Phillips, L. J., Velakoulis, D., & Pantelis, C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.12 · Cited by 328
The impact of environmental factors in severe psychiatric disorders
Schmitt, A., Malchow, B., Hasan, A., & Falkai, P. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00019 · Cited by 322
Neuroinflammation in schizophrenia especially focused on the role of microglia
Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314
van Haren, N. E. M., Hulshoff Pol, H. E., Schnack, H. G., Cahn, W., Mandl, R. C. W., Collins, D. L., Evans, A. C., & Kahn, R. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301347 · Cited by 311
A systematic review of the effects of antipsychotic drugs on brain volume
Moncrieff, J., & Leo, J. (2010) · Psychological Medicine · doi:10.1017/s0033291709992297 · Cited by 309
Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals
Sun, D., Phillips, L., Velakoulis, D., Yung, A., McGorry, P. D., Wood, S. J., van Erp, T. G. M., Thompson, P. M., Toga, A. W., Cannon, T. D., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.026 · Cited by 296
Apoptotic mechanisms and the synaptic pathology of schizophrenia
Glantz, L. A., Gilmore, J. H., Lieberman, J. A., & Jarskog, L. F. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.014 · Cited by 292
Self-citationMcGorry, P. D., Nelson, B., Goldstone, S., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 279
Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S., Dunn, G., & Deakin, B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 279
van Haren, N. E. M., Pol, H. E. H., Schnack, H. G., Cahn, W., Brans, R., Carati, I., Rais, M., & Kahn, R. S. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.004 · Cited by 276
Vita, A., De Peri, L., Deste, G., Barlati, S., & Sacchetti, E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.008 · Cited by 275
Juster, R.-P., Bizik, G., Picard, M., Arsenault-Lapierre, G., Sindi, S., Trepanier, L., Marin, M.-F., Wan, N., Sekerovic, Z., Lord, C., et al. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000289 · Cited by 268
Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., Erdag, S., Jahn, H., Degner, D., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001907 · Cited by 258
Lui, S., Deng, W., Huang, X., Jiang, L., Ma, X., Chen, H., Zhang, T., Li, X., Li, D., Zou, L., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020183 · Cited by 257
Brain Growth of the Domestic Pig (Sus scrofa) from 2 to 24 Weeks of Age: A Longitudinal MRI Study
Conrad, M. S., Dilger, R. N., & Johnson, R. W. (2012) · Developmental Neuroscience · doi:10.1159/000339311 · Cited by 187
Ranft, K., Dobrowolny, H., Krell, D., Bielau, H., Bogerts, B., & Bernstein, H.-G. (2010) · Psychological Medicine · doi:10.1017/s0033291709990821 · Cited by 183
Koo, M.-S., Levitt, J. J., Salisbury, D. F., Nakamura, M., Shenton, M. E., & McCarley, R. W. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.7.746 · Cited by 175
Vernon, A. C., Natesan, S., Modo, M., & Kapur, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.010 · Cited by 173
Seok, J.-H., Park, H.-J., Chun, J.-W., Lee, S.-K., Cho, H. S., Kwon, J. S., & Kim, J.-J. (2007) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2007.02.002 · Cited by 168
“, 2004), as well as a report that gray matter volume was decreased after haloperidol medication and not significantly changed after olanzapine medication (Lieberman et al., 2005).”
BackgroundTai, S., & Turkington, D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp080 · Cited by 154
Hasan, A., Nitsche, M. A., Rein, B., Schneider-Axmann, T., Guse, B., Gruber, O., Falkai, P., & Wobrock, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.017 · Cited by 156
Progressive changes of white matter integrity in schizophrenia revealed by diffusion tensor imaging
Mori, T., Ohnishi, T., Hashimoto, R., Nemoto, K., Moriguchi, Y., Noguchi, H., Nakabayashi, T., Hori, H., Harada, S., Saitoh, O., et al. (2007) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2006.09.004 · Cited by 132
Heritability of Changes in Brain Volume Over Time in Twin Pairs Discordant for Schizophrenia
Brans, R. G. H., van Haren, N. E. M., van Baal, G. C. M., Schnack, H. G., Kahn, R. S., & Pol, H. E. H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1259 · Cited by 129
Tracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Neuroendocrine profile in a rat model of psychosocial stress: Relation to oxidative stress
Colaianna, M., Schiavone, S., Zotti, M., Tucci, P., Morgese, M. G., Bäckdahl, L., Holmdahl, R., Krause, K.-H., Cuomo, V., & Trabace, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4569 · Cited by 107
Carpenter, W. T., Bustillo, J. R., Thaker, G. K., van Os, J., Krueger, R. F., & Green, M. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990286 · Cited by 99
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Yoshida, T., McCarley, R. W., Nakamura, M., Lee, K., Koo, M.-S., Bouix, S., Salisbury, D. F., Morra, L., Shenton, M. E., & Niznikiewicz, M. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.004 · Cited by 74
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Falkai, P., Malchow, B., Wobrock, T., Gruber, O., Schmitt, A., Honer, W. G., Pajonk, F.-G., Sun, F., & Cannon, T. D. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0383-y · Cited by 68
Hypothalamus and pituitary volume in schizophrenia: a structural MRI study
Klomp, A., Koolschijn, P. C. M. P., Hulshoff Pol, H. E., Kahn, R. S., & Van Haren, N. E. M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000794 · Cited by 59
Morais, M., Patrício, P., Mateus-Pinheiro, A., Alves, N. D., Machado-Santos, A. R., Correia, J. S., Pereira, J., Pinto, L., Sousa, N., & Bessa, J. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.120 · Cited by 56
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
Zierhut, K. C., Schulte-Kemna, A., Kaufmann, J., Steiner, J., Bogerts, B., & Schiltz, K. (2013) · Cortex · doi:10.1016/j.cortex.2012.08.027 · Cited by 26
Hamasaki, Y., Nakayama, T., Hikida, T., & Murai, T. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03049-w · Cited by 11
Amygdalar gray matter volume and social relating in schizophrenia
Günther, V., Lindner, C., Dannlowski, U., Kugel, H., & Suslow, T. (2016) · Neuropsychobiology · doi:10.1159/000458528 · Cited by 8
Metadata
- Authors
- Lieberman, J. A.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-01
- Volume
- 62
- Issue
- 4
- Pages
- 361
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2145240519
- Cited by
- 801
- References
- 47
- FWCI
- 35.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.